hVIVO (LON:HVO) Stock Keeps “Buy” Rating at Peel Hunt

hVIVO (LON:HVO)‘s stock had its “buy” rating reissued by equities researchers at Peel Hunt in a research note issued on Monday, October 12th, Digital Look reports. They currently have a GBX 14 target price on the stock. Peel Hunt’s target price would indicate a potential upside of 144.33% from the stock’s previous close.

hVIVO Stock Down 1.2%

Shares of hVIVO stock traded down GBX 0.07 during trading on Monday, hitting GBX 5.73. 403,892 shares of the stock were exchanged, compared to its average volume of 2,396,514. The company has a debt-to-equity ratio of 43.38, a current ratio of 1.21 and a quick ratio of 1.16. The firm’s 50-day moving average price is GBX 6.38 and its 200 day moving average price is GBX 7.14. The stock has a market cap of £39.45 million, a price-to-earnings ratio of -3.22 and a beta of 1.69. hVIVO has a 12-month low of GBX 4.30 and a 12-month high of GBX 11.

hVIVO (LON:HVO) last posted its earnings results on Tuesday, September 15th. The company reported GBX (0.82) EPS for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. As a group, analysts forecast that hVIVO will post 1.55 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.